Randall Lutter, Ph.D. Deputy Commissioner for Policy U.S. Food and Drug Administration May 2009 Addressing Challenges of Economically-Motivated Adulteration.

Slides:



Advertisements
Similar presentations
Biopharmaceutical Quality
Advertisements

Food Advisory Committee Meeting Risk assessments and susceptible life stages and populations December 16, 2014 Rachel Osterman Associate Chief Counsel,
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
FDA Economically Motivated Adulteration Conference 119.
Food Drug and Cosmetic Act 1938
Strengthening the Medical Device Clinical Trial Enterprise
Cayuga Milk Ingredients Using Advanced Technology to Produce High Quality Milk Ingredients for the World.
Food Safety Export Assurance System Requirements for Dairy Products Confidential to Fonterra Co-operative Group September 2014 Malcolm Bailey – Fonterra.
Government Agencies HUM-FNW-3 Unit 4. USDA United States Department of Agriculture Mission Statement We provide leadership on food, agriculture, natural.
Pure Foods and Drugs Act of 1906 Food Law FSC-421 “Lawdoc”
Understanding CGMPs – What Attorneys Need to Know The Nuts & Bolts of CGMPs: FDA Guidance for Industry Paula R. Katz Acting Branch Chief, Regulatory Policy.
Comments on Economically Motivated Adulteration Xuman Amanda Tian Research Associate, Food Safety Program Center for Science in the Public Interest
1 “Economically Motivated Adulteration FDA Public Meeting” May 1, 2009 Craig W. Henry Ph.D. Senior Vice President and Chief Operating Officer, Scientific.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
DSHEA and Bioavailability Elizabeth A. Yetley, Ph.D. Ctr. Food Safety & Applied Nutrition Food and Drug Administration.
Pharma & Healthcare Logistics Development Roadmap for Luxembourg T h e r e i s s o m e t h i n g g o i n g o n i n L u x e m b o u r g ! T A S T r u s.
Proposed Rules to Help Ensure the Safety of Imported Food 1.
1 CFSAN Chemical Signal Detection and Management System Presentation to Food Advisory Committee Donald Zink, Ph.D. Director, Senior Science Advisor Staff.
1 The Bioterrorism Act and Food 2217 Steven C Seideman Extension Food Processing Specialist Cooperative Extension Service University of Arkansas.
AFLATOXIN REGULATORY ISSUES Garnett E. Wood, Ph.D. Food and Drug Administration Center for Food Safety and Applied Nutrition Center for Food Safety and.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.
Prepared by: Taruna Navraksha Irfaan Shashi Food Quality & Certification.
Mike Murray Chair of EFPIA EH&S AHG MPA Conference Uppsala
Proposed Rule for Preventive Controls for Animal Food 1.
1 Proposed amendment of the Harmful Substances in Food Regulations (Cap. 132AF) Centre for Food Safety 3 June 2011.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
September 22, 2015 NOAA’s Seafood Safety and Quality Programs: Meeting the Challenges of a Global Seafood Supply.
Legislation Project: Federal Food, Drug, and Cosmetic Act 1938 Catherine DeMarco.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.
Regulation and Labeling Food Technology Ch 26. Regulation and Labeling The Food and Drug Administration (FDA) and the United States Dept of Agriculture.
Center for Food Safety and Applied Nutrition (CFSAN) Golriz Khadem And Ryan Leitz.
Dietary Supplements. Definition by DSHEA Product that is to supplement a healthy diet. Includes ingredients such as vitamins, minerals, herbs, botanicals,
Food and Drug Administration & Outbreaks
Non-O157 STEC: New Challenges / Practical Limitations / Next Steps Robert L. Buchanan HHS Food and Drug Administration Center for Food Safety and Applied.
Preventive Controls for Human Food S upplemental Proposal 1
Foreign Supplier Verification Programs Supplemental Proposal 1.
Proposed Rule for Preventive Controls for Animal Food.
Proposed Rule: 21 CFR 507 Proposed Rule for Preventive Controls for Animal Food 1.
Overview of FDA's Regulatory Framework for PET Drugs
Suspected Economically Motivated Adulteration of FDA-Regulated Products Cosmetics and Personal Care Products John E. Bailey Executive Vice President -
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Food Safety – An Issue of Public Health Concern
Joe Collins – MD Ornua Dairy Trading & Ingredients
PwC Informations- gold assets. 2 Introduction 3 Central and Eastern EuropeGlobal Number of companies that have been victims of economic crime in the.
Final Rule for Preventive Controls for Animal Food 1 THE FUTURE IS NOW.
Mission, Organization, and Operations Presentation by Gray Etheredge and Cathy Chang January 20, 2004.
United States Department of Agriculture Food Safety and Inspection Service Overview of Trim Sampling Compliance Guidelines and Discussion Daniel Engeljohn,
Product Recall Laws in China Xiangwen Liu Partner King & Wood PRC Lawyers.
U.S. Food and Drug Administration Food Protection Plan David W. K. Acheson, M.D., F.R.C.P. Associate Commissioner for Foods.
FSMA Communications and Engagement for International Stakeholders March 21, 2016 Julie Moss, PhD, RD Deputy Director, International Affairs Staff, Center.
1 Strategies and Technologies to Improve the Detection of Pharmaceutical Adulterants Michael Hunnicutt, Ph.D. Pfizer Global Quality Operations Analytical.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Food Science: An Old but New Subject
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
AFLATOXIN REGULATORY ISSUES
Executive Director, Registrar Corp
The Quality of Working Life: Promoting a Healthy Agenda
Food Additives Project
“Economically Motivated Adulteration FDA Public Meeting” May 1, 2009
Overview of FDA Food Inspections
Global Supply & Demand of Soybeans and Soy Oil
Jason Dietz Office of Food Additive Safety October 5, 2018
Final Rule on Foreign Supplier Verification Programs
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
Presentation transcript:

Randall Lutter, Ph.D. Deputy Commissioner for Policy U.S. Food and Drug Administration May 2009 Addressing Challenges of Economically-Motivated Adulteration

2 Recent Cases Melamine In Food –Added to infant formula & dairy apparently to enhance perceived quality –Added to flour intended for pet food apparently to enhance protein content Contaminated Heparin –Contaminated with oversulfated chondroitin sulphate apparently to evade an analytical test Diethylene Glycol –Drugs and foods contaminated from substitution with toxic syrup. At least eight mass poisonings around the world in the past two decades. Common theme: contaminant thought to have been intentionally introduced for economic gain.

3 Working Definition Fraudulent, intentional substitution or addition of a substance in a product for the purpose of increasing the apparent value of the product or reducing the cost of its production, i.e., for economic gain.

4 Common Theme Suggests a New Approach New Strategy –Identify new efficient ways of predicting risk, based on new risk factors such as assays, ingredients, product characteristics, early signals, etc, associated with economically motivated adulteration. New Process –Formed internal work group –Sought advice from Science Board –Sought advice from other agencies –Public meeting (and other information)

5 Contact Us FDA does not wish to publicize sensitive information that could potentially be used by those who wish to profit from adulterating food or medical products or that identifies those that may be committing adulteration People with information about these or other problems they have encountered with FDA products may report such information at People with information pertaining to suspected criminal activity with regard to FDA-regulated products may contact FDA’s Office of Criminal Investigations at

6 Deliberate contamination for economic purposes is not new 1858: Sale of “swill milk” in NYC—milk derived from cows fed alcoholic mash that killed up to 8000 children in a year. New York Times, August 13, 1890:

7 Congressional Actions to Address Intentional Adulteration Federal Food and Drugs Act of finding food adulterated –If any substance has been mixed and packed with it so as to reduce or lower or injuriously affect its quality or strength. –If any substance has been substituted wholly or in part for the article. –If any valuable constituent of the article has been wholly or in part abstracted. –If it be mixed, colored, powdered, coated, or stained in a manner whereby damage or inferiority is concealed. Filled Milk Act of deeming “filled milk” adulterated –Filled milk means “any milk, cream, or skimmed milk, whether or not condensed, evaporated, concentrated, powdered, dried, or desiccated, to which has been added, or which has been blended or compounded with, any fat or oil other than milk fat, so that the resulting product is in imitation or semblance of milk, cream, or skimmed milk, whether or not condensed, evaporated, concentrated, powdered, dried, or desiccated.” Indeed, the effort of FDA to reduce risks associated with inadvertent contamination and poor quality control is relatively recent.

8 New Challenges: Globalization Globalization has raised economically motivated adulteration as a key concern. Volume of imported “lines” of FDA-regulated products has grown 14% annually since Imports of FDA-regulated products as a percent of US consumption: –Food: 15% * –Drugs: 27% ** –Devices: 22%** –Cosmetics: 9% ** –* USDA, Economic Research Service, September 2008 ** based on: US custom value and US value of shipments

9 New Challenges: Globalization Protection at the border is intrinsically more challenging –Inspections more costly overseas and equivalent state regulatory agencies do not exist. –Other information more scarce. Despite ongoing efforts at strengthening –We have opened new offices in China, India, Latin America and Europe to better ensure quality and safety of imported products.

10 Strategy for Identifying the “Next Melamine” Large-scale economically motivated contamination is likely where: Expected reward from adulteration > Expected cost of being discovered and penalized

11 General Questions What information should U.S. regulators seek and from what sources to help predict and prevent EMA? What further steps can U.S. regulators take to predict and prevent EMA? What are members of industry doing to prevent EMA? What further steps can industry take to prevent EMA? What recent examples of known or suspected EMA domestically and internationally should U.S. regulators study and learn from? What information do other organizations (including, but not limited to, trade organizations and security service providers) have that would be useful in predicting and preventing EMA? What are members of other organizations doing to prevent EMA? What are other government regulators within and outside of the U.S. doing to predict and address EMA? What indicators (economic-based, chemistry-based, etc.) might be used to detect potential EMA?

12 Questions About Attributes Of Products, Components / Ingredients That May Be At Risk For EMA: –What are attributes of products or components / ingredients of products that may cause them to be more vulnerable to EMA? –What food products are marketed based on measured content of certain constituents, such as content of certain proteins, certain fats, or certain sugars?

13 Questions About The Marketing Environment What changes relevant to the risk for EMA have occurred recently in: –The marketing environment of products or components/ingredients? –The sourcing and/or distribution of products? –The prices, output, imports or exports of products or components / ingredients? –The supply of components/ingredients or source materials for products?

14 Questions About Detection Methods: What analytical equipment or methods currently used by industry and regulators to establish the identity or quality of a product or its conformity to specifications may be inadequate to detect evidence of EMA or adulterated products or ingredients? Are there appropriate analytical methods/equipment that could be used instead of, or in addition to, existing methods or equipment in particular situations? What rapid methods can be used to detect adulteration of products or ingredients?

15 Additional Questions What systems are currently being used to track and verify components / ingredients from their source? Are there particular types of industry structures or supply chains that are especially vulnerable to or secure from potential EMA?

16 Today’s Agenda 5 panels –Academic –Pharmaceuticals –Foods –Dietary Supplements and Cosmetics –Public Interest Groups Questions from our panel Open public hearing at 3:45 Any comments may be submitted to the docket.

17 Thanks To Steven Solomon, Irene Chan, Kevin Whittlesley, and other FDA staff. For your participation and your help!